CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab' from SEC operating under the aegis of CDSCO

CuraTeQ Biologics Pvt. Ltd., a wholly owned subsidiary of Aurobindo Pharma Ltd, today received from Subject Experts Committee (SEC) operating under the aegis of CDSCO (Central Drugs Standard Control Organization) a recommendation for grant of marketing authorization of biosimilar trastuzumab. Trastuzumab biosimilar, supplied in single dose glass vials containing 150 mg and 420 mg lyophilized powder for concentrate for solution for infusion, is a humanized monoclonal antibody for treating metastatic breast cancer and early breast cancer that is human epidermal growth factor receptor 2 positive. CuraTeQ was asked to submit Phase IV clinical trial protocol to CDSCO within three months of receiving the marketing authorization.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1118.80 as compared to the previous close of Rs. 1150.00. The total number of shares traded during the day was 59838 in over 3272 trades.

The stock hit an intraday high of Rs. 1159.85 and intraday low of 1115.00. The net turnover during the day was Rs. 67577594.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 CuraTeQBiologics SME CDSCO MarketingAuthorization Tastuzumab Biosimilar